scholarly journals Peripheral neuropathy after viral eradication with direct‐acting antivirals in chronic HCV hepatitis: a prospective study

2021 ◽  
Author(s):  
Maria M. Zanone ◽  
Claudia Marinucci ◽  
Alessia Ciancio ◽  
Dario Cocito ◽  
Federica Zardo ◽  
...  
Keyword(s):  
Peripheral Neuropathy ◽  
Prospective Study ◽  
Hepatitis A ◽  
Direct Acting Antivirals ◽  
Viral Eradication ◽  
Chronic Hcv ◽  
Direct Acting ◽  
A Prospective Study

scholarly journals Neuropsychiatric performance and treatment of hepatitis C with direct-acting antivirals: a prospective study

2017 ◽  
Vol 4 (1) ◽  
pp. e000183 ◽  
Author(s):  
Sofia Volpato ◽  
Sara Montagnese ◽  
Alberto Zanetto ◽  
Matteo Turco ◽  
Michele De Rui ◽  
...  
Keyword(s):  
Hepatitis C ◽  
Prospective Study ◽  
Direct Acting Antivirals ◽  
Direct Acting ◽  
A Prospective Study

scholarly journals Salvage Therapy in Cancer Patients With Hepatitis C Infection Failing Direct-Acting Antivirals: A Prospective Study

2017 ◽  
Vol 4 (suppl_1) ◽  
pp. S204-S204
Author(s):  
Haley Pritchard ◽  
Deeksha Jandhyala ◽  
Minas Platon Economides ◽  
Jeff Hosry ◽  
Harrys Torres
Keyword(s):  
Hepatitis C ◽  
Prospective Study ◽  
Cancer Patients ◽  
Salvage Therapy ◽  
Direct Acting Antivirals ◽  
Hepatitis C Infection ◽  
Direct Acting ◽  
A Prospective Study

When Coadministration Cannot Be Avoided: Real World Experience of Direct Acting Antivirals for the Treatment of Hepatitis C Virus Infection in Patients on First Generation Anticonvulsants

2020 ◽  
pp. 089719002097776
Author(s):  
Kayla M. Natali ◽  
Humberto R. Jimenez ◽  
Jihad Slim
Keyword(s):  
Drug Interaction ◽  
Hepatitis C ◽  
Clinical Cure ◽  
First Generation ◽  
Virologic Response ◽  
Hcv Infection ◽  
Direct Acting Antivirals ◽  
Chronic Hcv Infection ◽  
Chronic Hcv ◽  
Direct Acting

Background Coadministration of direct-acting antivirals (DAAs) for chronic hepatitis C virus (HCV) infection and first generation anticonvulsants is currently not recommended due to a drug-drug interaction that could potentially lead to subtherapeutic DAA levels and subsequent treatment failure. Currently, there is limited data evaluating this interaction and timely treatment of HCV infection with DAAs is imperative to prevent liver-related morbidity and mortality. Methods A retrospective case series evaluating clinical cure of chronic HCV infection, defined as sustained virologic response (SVR) 12 weeks after completion of DAA therapy, in patients from three inner-city clinics who remained on first generation anticonvulsants during the treatment course. Results A total of five patients received standard dose DAAs for treatment of chronic HCV infection while being maintained on first generation anticonvulsants. The most common HCV genotype was 1a (80%), followed by 1b (20%). The majority of patients were treated with glecaprevir/pibrentasvir (80%) for eight weeks and one patient was treated with ledipasvir/sofosbuvir for 12 weeks. Anticonvulsant regimens consisted of carbamazepine, phenytoin, phenytoin plus phenobarbital, phenytoin plus levetiracetam, and phenobarbital plus lacosamide. All five patients achieved sustained virologic response (SVR) despite this drug-drug interaction. Conclusion Although every effort to prevent concomitant use of DAAs and potent inducers should be made, clinical cure may still be achieved in patients whom cannot avoid this coadministration.

The occurrence of thrombotic thrombocytopenic purpura during treatment of HCV with direct-acting antiviral agents

2018 ◽  
Vol 1 (1) ◽  
pp. 1-9
Author(s):  
Amr Hanafy ◽  
◽  
Waseem Seleem ◽  
Salem Mohamed ◽  
Keyword(s):  
Thrombotic Thrombocytopenic Purpura ◽  
Hemolytic Anemia ◽  
Peripheral Blood Smear ◽  
Hcv Infection ◽  
Severe Thrombocytopenia ◽  
Direct Acting Antivirals ◽  
Thrombocytopenic Purpura ◽  
Direct Acting Antiviral ◽  
Chronic Hcv ◽  
Direct Acting

Background and aim Experts have reported thrombocytopenia linked to chronic liver disease in up to 70% in patients with advanced fibrosis and portal hypertension. Thrombotic thrombocytopenic purpura (TTP) occurrence with HCV infection is a rare and life-threatening event. We aimed to investigate the cause of disturbed conscious level, acute hemolytic anemia, and severe thrombocytopenia in a male patient with chronic HCV and under treatment with direct-acting antivirals. Case report: Development of severe thrombocytopenia, acute hemolytic anemia, neurological symptoms in the form of fits and coma in a 32- year- old man with chronic HCV infection after one week of treatment with direct-acting antivirals (sofosbuvir 400mg PO daily, and daclatasvir 60 mg PO daily). Brain CT was normal, with a negative Coombs test and the presence of schistocytes in the peripheral blood smear. The patient presentation was suggestive of thrombotic thrombocytopenic purpura (TTP). Conclusion: This is a case of TTP after one week of direct-acting antiviral drugs despite the safety profile of these medications. Studying the pathophysiology of TTP after DAAs needs more clarifications.

Use of an alpha lipoic, methylsulfonylmethane and bromelain dietary supplement (Opera®) for chemotherapy-induced peripheral neuropathy management, a prospective study

2017 ◽  
Vol 34 (3) ◽  
Author(s):  
Isacco Desideri ◽  
Giulio Francolini ◽  
Carlotta Becherini ◽  
Francesca Terziani ◽  
Camilla Delli Paoli ◽  
...  
Keyword(s):  
Peripheral Neuropathy ◽  
Prospective Study ◽  
Dietary Supplement ◽  
A Prospective Study
Sign in / Sign up

Export Citation Format

Share Document